{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"52"},{"groupId":"OG002","value":"19"},{"groupId":"OG003","value":"21"}]}],"title":"AEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"4"}]}],"title":"SAEs"}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"54"},{"groupId":"OG002","value":"25"},{"groupId":"OG003","value":"29"}],"units":"Participants"}],"description":"AEs included both non-SAEs and SAEs and the same participant can have both SAEs and as well non-SAEs.","groups":[{"description":"During Combination Treatment Phase, participants received amatuximab 5 mg/kg, infusion, intravenously, once weekly in 21-day cycles and pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2, infusion, intravenously, on Day 1 of each 21-day cycle for 6 cycles.","id":"OG000","title":"Combination Treatment Phase:Amatuximab + Pemetrexed +Cisplatin"},{"description":"During Combination Treatment Phase, participants received placebo matched to amatuximab infusion, intravenously, once weekly in 21-day cycles and pemetrexed 500 mg/m\\^2 and cisplatin 75 mg/m\\^2, infusion, intravenously, on Day 1 of each 21-day cycle for 6 cycles.","id":"OG001","title":"Combination Treatment Phase: Placebo + Pemetrexed + Cisplatin"},{"description":"Following completion of the Combination Treatment Phase, participants who had not progressed entered the Maintenance Phase and continued to receive amatuximab 5 mg/kg, infusion, intravenously, once weekly until disease progression.","id":"OG002","title":"Maintenance Treatment Phase: Amatuximab"},{"description":"Following completion of the Combination Treatment Phase, participants who had not progressed entered the Maintenance Phase and received placebo matched to amatuximab infusion, intravenously, once weekly until disease progression.","id":"OG003","title":"Maintenance Treatment Phase: Placebo"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The safety analysis set was defined as all randomized participants who received at least 1 dose of study drug.","reportingStatus":"POSTED","timeFrame":"Baseline up to 3 years","title":"Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)","type":"PRIMARY","unitOfMeasure":"Participants"}